FluoroPharma Medical, Inc. announced that phase II Clinical trials will be conducted at Massachusetts General Hospital for BFPET, (18)F-TPP, the company's imaging agent under evaluation for measuring cardiovascular blood flow. BFPET has the potential for producing images with clear diagnostic qualities as well as increased resolution. The greater sensitivity will provide doctors with earlier and more accurate information for more effective patient management.

The phase II trial for BFPET is an open label study designed to assess the safety and diagnostic performance of BFPET. Results are expected over the next six months.